Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- NCVC Announces List of Generics Adopted by It
March 9, 2009
- Cell Cultured Vaccine for Japanese Encephalitis from BIKEN Approved
March 9, 2009
- Pharmacists' Cooperation Essential to Increase Use of Generics
March 9, 2009
- Prasugrel Approved in EU
March 9, 2009
- 2nd OTC Drug Wholesaler with Nationwide Coverage to Be Created
March 9, 2009
- GSK's Tykerb Recommended for Approval
March 9, 2009
- Sanjou General Hospital Causes Stir by Switching Back to In-house Prescriptions
March 9, 2009
- 2 Combinations of ARB and Diuretic to Become Available Soon
March 9, 2009
- Opposition Disagrees with Reappointment of Prof. Maeda as Chuikyo Member
March 9, 2009
- Data from Ranbaxy Plant Are Falsified: FDA
March 9, 2009
- Chugai's Avastin Should Be Indicated for Stomach Cancer
March 9, 2009
- Tasigna Recommended in 2nd-Line Therapy: Prof. Ohyashiki
March 9, 2009
- Constipation Should Be Treated by Physicians: Dr Hongo
March 9, 2009
- Chugai Licenses Nitazoxanide from Romark Lab.
March 2, 2009
- Acquisition of Local Company an Option for Marketing Lurasidone in US: DSP
March 2, 2009
- GSK to Tie Up with Nippon Kayaku to Market Lapatinib in Japan
March 2, 2009
- Mr Shoda Feels the Pinch of the Global Financial Crisis
March 2, 2009
- BUSINESS NEWS IN BRIEF
March 2, 2009
- Korosho Suggests Re-Pricing Based Only on Increases in Sales
March 2, 2009
- Reductions in Makers' Invoice Prices Have Not Been Sufficient
March 2, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…